Twist Bioscience Earnings Reports

Twist Bioscience ended Q4 2025 with strong revenue of $99M, surpassing guidance. Gross margin improved to 51.3%, and the company significantly narrowed its net loss. Adjusted EBITDA was close to breakeven.

Twist Bioscience delivered strong results in Q3 2025 with record revenue, improved gross margins, and a swing to net income, driven by solid performance in both SynBio and NGS segments.

Twist Bioscience delivered $92.8 million in revenue for Q2 FY25, with a significant improvement in gross margin to 49.6% and a reduced adjusted EBITDA loss of $14.8 million, indicating strong progress toward profitability.

Twist Bioscience reported a strong start to fiscal year 2025, achieving record revenue of $88.7 million, a 24% increase compared to the same period last year, and a gross margin of 48.3%, which is a 7.8 margin points improvement year-over-year.

Twist Bioscience reported record revenue of $84.7 million for Q4 2024, a 27% increase compared to the same period last year. The gross margin improved to 45.1%. The company exceeded its guidance for the quarter and year, ending the fiscal year with $313.0 million in revenue and a strong cash position.

Twist Bioscience reported a strong fiscal third quarter with record revenue of $81.5 million, a 28% increase year-over-year, and a gross margin improvement to 43.3%. The company exceeded revenue guidance and targets for cash burn and gross margin.

Twist Bioscience reported a strong second quarter with revenue increasing to $75.3 million, a 25% increase year-over-year, and orders increasing to $93.2 million, a 45% increase year-over-year. The company's gross margin improved to 41%, and they are focused on achieving profitability.

Twist Bioscience reported a strong start to fiscal year 2024, achieving record revenue of $71.5 million, a 32% increase compared to the same period last year. The company's gross margin was 40.5%.

Twist Bioscience reported its Q4 and Full Year Fiscal 2023 financial results, with Q4 revenue growing to $66.9 million compared to $57.3 million for the same period of fiscal 2022. The company's FY23 revenue reached $245.1 million, a 20% increase over the previous year. Net loss for Q4 decreased to $46.2 million, or $0.81 per share, compared to $51.1 million, or $0.91 per share, for the same period last year.

Twist Bioscience reported record revenue of $63.7 million for the third quarter of fiscal year 2023, a 14% increase compared to the same period in fiscal 2022. The company's core business, comprised of SynBio and NGS, delivered strong results. The company shipped products to approximately 2,200 customers and approximately 171,000 genes during the quarter.

Twist Bioscience reported a strong quarter, exceeding revenue guidance and breaking the $60 million revenue threshold for the first time. The company also announced decisive and proactive actions aimed at accelerating its path to profitability.

Twist Bioscience reported a solid start to the year with strong revenue growth across SynBio, NGS, and biopharma, alongside robust order increases. The company shipped its first products from the Factory of the Future and expanded its customer base.

Twist Bioscience reported a revenue of $57.3 million for the fourth quarter of fiscal year 2022, compared to $38.0 million for the same period of fiscal year 2021. The net loss attributable to common stockholders for the fourth quarter of fiscal 2022 was $51.1 million, or $0.91 per share, compared to $41.2 million, or $0.84 per share, for the same period of fiscal 2021.

Twist Bioscience reported record revenue of $56.1 million for the third quarter of fiscal 2022, a 60% increase compared to the same period in fiscal 2021. The company also increased its revenue guidance for the full year fiscal 2022 to $203 million.

Twist Bioscience reported record revenue of $48.1 million for the second quarter of fiscal year 2022, a 54% increase compared to the previous year. Orders also increased by 32% to $55.0 million. Twist Biopharma added 5 new partnerships and 15 programs. The company is focused on managing cash burn and expects adjusted EBITDA break even for the core business upon reaching $300 million in revenue for synbio and NGS.

Twist Bioscience reported a strong start to the year with record orders and revenue. The company's biopharma team added new partners and programs, with the first Twist Biopharma-discovered antibody expected to enter clinical trials this year.

Twist Bioscience reported financial results for the fourth quarter and full year fiscal 2021, achieving record revenues in fiscal 2021 of $132.3M, a 47% increase over fiscal 2020.

Twist Bioscience reported strong financial results for the third quarter of fiscal year 2021, with revenue growth of 65% year-over-year and a gross margin of 40%. The company raised its revenue guidance based on continued strength across its business.

Twist Bioscience reported strong growth in all four areas of its business for the second quarter of fiscal year 2021. The company saw increasing revenue and strong orders, with new biopharma partnerships and progress in data storage density.

Twist Bioscience reported a strong first quarter for fiscal year 2021, with total revenues of $28.2 million, compared to $17.2 million for the same period of fiscal 2020. The company's net loss was $32.9 million, or $0.72 per share, compared to $55.6 million, or $1.69 per share, for the first quarter of fiscal 2020. As of December 31, 2020, the company had $587.3 million in cash, cash equivalents and short-term investments.

Twist Bioscience reported strong fourth-quarter and full-year fiscal 2020 financial results, with a significant increase in revenue and orders compared to the previous year. The company's synthetic biology and NGS product lines drove the overarching success.

Twist Bioscience reported a strong third quarter with total revenues of $21.2 million, a 56% increase compared to the same period in 2019. The company's net loss was $28.2 million, or $0.67 per share. They ended the quarter with $311.8 million in cash and short-term investments.

Twist Bioscience reported a strong second quarter with revenues of $19.3 million, a 42% increase compared to the same period last year. The company launched new products for SARS-CoV-2 testing and saw an increase in its customer base.

Twist Bioscience reported a strong start to fiscal year 2020, with revenues of $17.2 million, a 49% increase over the same period last year. The company also reached a settlement agreement with Agilent, removing uncertainty and paving the way for future growth.